Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.
Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ (PVT) viral vector platform for developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results